Adrenal insufficiency, be aware of drug interactions!

2019 ACTH Adrenal Adrenal insufficiency Adult Belgium CT scan CYP 3A4 inducers* Corticotropin-releasing hormone stimulation test Cortisol DHEA Sulphate Error in diagnosis/pitfalls and caveats Fludrocortisone General practice Glucocorticoids Hydrocortisone Hyperpigmentation Hypotension Male Mantoux test Mineralocorticoids Myalgia Myambutol* Nicotibine* October PET scan Pyridoxine* Renin (blood) Rifampicin* Tebrazid* Tuberculosis Tuberculostatic drugs* Tuberculous adrenalitis* White

Journal

Endocrinology, diabetes & metabolism case reports
ISSN: 2052-0573
Titre abrégé: Endocrinol Diabetes Metab Case Rep
Pays: England
ID NLM: 101618943

Informations de publication

Date de publication:
03 Oct 2019
Historique:
received: 11 08 2019
accepted: 06 09 2019
entrez: 4 10 2019
pubmed: 4 10 2019
medline: 4 10 2019
Statut: aheadofprint

Résumé

A 42-year-old man with complaints of muscle soreness and an increased pigmentation of the skin was referred because of a suspicion of adrenal insufficiency. His adrenocorticotropic hormone and cortisol levels indicated a primary adrenal insufficiency (PAI) and treatment with hydrocortisone and fludrocortisone was initiated. An etiological workup, including an assessment for anti-adrenal antibodies, very long-chain fatty acids, 17-OH progesterone levels and catecholamine secretion, showed no abnormalities. 18Fluorodeoxyglucose positron emission tomography/CT showed bilateral enlargement of the adrenal glands and bilateral presence of an adrenal nodule, with 18fluorodeoxyglucose accumulation. A positive tuberculin test and positive family history of tuberculosis were found, and tuberculostatic drugs were initiated. During the treatment with the tuberculostatic drugs the patient again developed complaints of adrenal insufficiency, due to insufficient dosage of hydrocortisone because of increased metabolism of hydrocortisone. Shrinkage of the adrenal nodules following tuberculostatic treatment supports adrenal tuberculosis being the common aetiology. The tuberculostatic drug rifampicin is a CYP3A4 inducer, increasing the metabolism of hydrocortisone. Increase the hydrocortisone dosage upon initiation of rifampicin in case of (adrenal) tuberculosis. A notification on the Addison's emergency pass could be considered to heighten physician's and patients awareness of hydrocortisone drug interactions.

Identifiants

pubmed: 31581123
doi: 10.1530/EDM-19-0062
pii: EDM190062
pmc: PMC6790904
doi:
pii:

Types de publication

Journal Article

Langues

eng

Références

Clin Endocrinol (Oxf). 2001 May;54(5):633-9
pubmed: 11380494
J Clin Endocrinol Metab. 1984 Dec;59(6):1204-6
pubmed: 6490796
BMJ Case Rep. 2019 Mar 14;12(3):null
pubmed: 30872343
PLoS One. 2015 Aug 28;10(8):e0135975
pubmed: 26317782
N Engl J Med. 1996 Oct 17;335(16):1206-12
pubmed: 8815944
Lancet. 2014 Jun 21;383(9935):2152-67
pubmed: 24503135
Clin Endocrinol (Oxf). 1994 Jul;41(1):53-6
pubmed: 8050132
J Intern Med. 2014 Feb;275(2):104-15
pubmed: 24330030
J Clin Endocrinol Metab. 2016 Feb;101(2):364-89
pubmed: 26760044

Auteurs

Elke Thijs (E)

Internal Medicine, University Hospital, Ghent, Belgium.

Katrien Wierckx (K)

Endocrinology, OLV Hospital, Aalst, Belgium.

Stefaan Vandecasteele (S)

Nephrology - Infectious Diseases, A.Z.-Sint Jan, Bruges, Belgium.

Annick Van den Bruel (A)

Endocrinology, A.Z.-Sint Jan, Bruges, Belgium.

Classifications MeSH